NCT00123929View on ClinicalTrials.gov

Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Breast Cancer
Interventions
DRUG

docetaxel

100 mg/m2 every 3 weeks times 4

DRUG

doxorubicin

75 mg/m2 every 3 weeks times 4

Trial Locations (1)

28040

Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid

All Listed Sponsors
collaborator

UNC Lineberger Comprehensive Cancer Center

OTHER

lead

Hospital San Carlos, Madrid

OTHER

NCT00123929 - Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer | Biotech Hunter | Biotech Hunter